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Xian-Tao Zeng1†, Wei Luo2†, Pei-Liang Geng3, Yi Guo4, Yu-Ming Niu1 and Wei-Dong Leng1*Abstract
Background: Several epidemiological studies have previously investigated the association between the TP53 codon
72 polymorphism and oral squamous cell carcinoma (OSCC) susceptibility; however, current results are inconsistent.
We therefore performed this meta-analysis to thoroughly investigate any association among Asian patients.
Methods: A comprehensive search of PubMed and Embase databases was performed up to December 2013. We
only considered studies consisting of patients diagnosed with OSCC by pathological methods. Statistical analyses
were performed using Review Manager (RevMan) 5.2 software and odds ratios (ORs) with 95% confidence intervals
(CIs) were used to assess the association.
Results: A total of 11 case–control studies involving 2,298 OSCC patients and 2,111 controls were included. We found no
association between the TP53 codon 72 polymorphism and OSCC susceptibility [(OR = 0.77, 95% CI = 0.48–1.22) for Arg vs.
Pro; (OR = 0.67, 95% CI = 0.31–1.43) ArgArg vs. ProPro; (OR = 1.14, 95% CI = 0.97–1.35) ArgPro vs. ProPro; (OR = 0.85, 95%
CI = 0.53–1.34) (ArgPro + ArgArg) vs. ProPro; or (OR = 0.34, 95% CI = 0.34–1.23) for ArgArg vs. (ProPro + ArgPro)]. However,
subgroup analysis demonstrated an association between the TP53 codon 72 polymorphism and human papillomavirus
(HPV)-related OSCC patients. Although statistical heterogeneity was detected, there was no evidence of publication bias.
Conclusions: Current results suggest that the TP53 codon 72 polymorphism is not associated with OSCC in Asians
without the presence of HPV infection. Further research is necessary to determine if such a relationship exists in
HPV-related OSCC patients.
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Meta-analysisBackground
Oral cancer is ranked as the 11th most common type of
cancer worldwide [1], with a higher prevalence in South
and Southeast Asian countries such as India, Bangladesh,
China, and Sri Lanka [2]. Oral squamous cell carcinoma
(OSCC) originates from the squamous cells that cover the
surface of the mouth and is a major type of oral cancer,
accounting for more than 90% of cases [3]. Tobacco use
(chewing with or without smoking), alcohol consumption,
and human papillomavirus (HPV) infection are important* Correspondence: lengtaihe@163.com
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unless otherwise stated.risk factors for development of OSCC [4,5]; however,
molecular mechanisms relating to OSCC are still
being investigated, while genetic predisposition is gaining
increasing attention [6-8].
The tumor protein p53 (TP53) gene, located on
chromosome 17p13, is one of the most frequently
mutated genes in human cancers and has been reported to
be a significant determining factor in carcinogenesis [9].
The codon 72 polymorphism (rs1042522) is located in exon
4 of TP53 gene, and involves a CCC→CGC transition
leading to a proline (Pro)→ arginine (Arg) amino acid
substitution at position 72 (Pro72Arg) (http://www.
ncbi.nlm.nih.gov/snp/?term=rs1042522) [10]. Many pub-
lished meta-analyses have indicated that the TP53 codon
72 polymorphism might be associated with increasedtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Study selection flow chart.
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http://www.biomedcentral.com/1471-2407/14/469susceptibility to cervical cancer [11], bladder cancer [12],
and nasopharyngeal carcinoma [13].
Several previous studies have explored the association
between the TP53 codon 72 polymorphism and OSCC
susceptibility; however, existing results are inconsistent.
In 2009, Zhuo et al. performed a meta-analysis of nine
case–control studies and found that the TP53 codon 72
polymorphism might be a risk factor for oral carcinoma
[14]. This is in agreement with another meta-analysis of
17 case–control studies by Jiang et al. published in 2013
[15]. Both meta-analyses included patients with OSCC
but did not stratify the condition as a separate subgroup
[14,15]. Additionally, several more recent studies have
since been published. Therefore, we conducted this meta-
analysis to obtain accurate and up-to-date estimates of the
association between the TP53 codon 72 polymorphism
and OSCC susceptibility in Asians. Subgroup analysis was
also performed to investigate any potential HPV-specific
effects.
Methods
This meta-analysis adheres to the recommended Preferred
Reporting Items for Systematic Reviews and Meta-Analyses
(PRISMA) guidelines [16].
Inclusion criteria
We included case–control studies that met the following
eligibility criteria: (1) evaluated the association between the
TP53 codon 72 polymorphism and OSCC susceptibility inAsians; (2) included OSCC cases diagnosed by histologic
methods or clearly reported the type, and contained
healthy or cancer-free controls; (3) provided the number of
individual genotypes in both the case and control groups,
or enabled the genotypes to be calculated from available
published data; (4) published in English or Chinese; and
(5) used genotyping was polymerase chain reaction
(PCR) including PCR- polymerase chain reaction-
restriction fragment length polymorphism (RFLP) and
PCR- polymerase chain reaction-single strand confor-
mation polymorphism (SSCP) for genotyping.
Search strategy
We searched PubMed and Embase databases up to
December 10, 2013 with the following search items:
[(oral OR tongue OR mouth) AND (cancer OR carcinoma)
AND (p53 OR TP53) AND polymorphism]. Reference lists
of the included studies and published meta-analyses on
related topics were also screened for additional studies.
Data extraction
Two authors independently extracted the following trial
data from included studies: last name of the first author,
publication year, countries of origin, HPV status of cases,
source of control, number and genotyping distribution
of cases and controls, diagnostic method for OSCC,
genotyping method, and Hardy-Weinberg Equilibrium
(HWE) for controls [17]. Disagreements were resolved
by discussion.
Table 1 Characteristics of included studies







HPV Total ProPro ArgPro ArgArg Total ProPro ArgPro ArgArg
Tandle 2001 [19] India No 72 14 52 6 Histopathological PB 153 31 100 22 PCR <0.001
Nagpal 2002 [20] India Yes 110 21 58 31 Histological PB 26 2 11 13 PCR 0.876
Kietthubthew 2003 [21] Thailand No 97 21 44 32 Histological PB 97 28 34 35 PCR 0.004
Hsieh 2005 [22] China No 629 114 328 187 Histological PB 371 66 177 128 PCR-RFLP 0.723
Kuroda 2007 [24] Japan No 100 15 44 41 Histological HB 271 45 117 109 PCR-RFLP 0.159
Bau 2007 [23] China No 137 21 70 46 NA HB 105 22 65 18 PCR 0.139
Lin 2008 [25] China No 297 46 155 96 Histological PB 280 52 156 72 PCR-RFLP 0.085
Tu 2008 [26] China No 189 30 106 53 NA HB 116 15 60 41 PCR 0.337
Misra 2009 [27] India No 308 66 155 87 Histopathological HB 342 98 159 85 PCR 0.203
Saini 2011 [28] Malaysia Yes 99 37 40 22 NA HB 90 23 39 28 PCR 0.215
Saleem 2013 [29] Pakistan No 260 125 113 22 NA PB 260 33 23 204 PCR-SSCP <0.001
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We employed the fixed-effect analytical model first to
pool results of the included studies, and the I2 statistic
[18] was used to test for statistical heterogeneity. If I2 was
more than 40%, we switched to a random-effects model.
The odds ratios (ORs) and relevant 95% confidence
intervals (CIs) were used to quantify the strength of
association between the TP53 codon 72 polymorphism and
OSCC susceptibility using five genetic models: Arg vs. Pro,
ArgArg vs. ProPro, ArgPro vs. ProPro, (ArgPro +ArgArg)
vs. ProPro, and ArgArg vs. (ProPro +ArgPro). Additionally,
subgroups analyses based on HPV status, source of
controls, and HWE status for controls were performed.
Publication bias was detected by examination of funnel
plots. All statistical analyses were conducted using Review
Manager (RevMan) software (version 5.2 for Windows).
Results
Study characteristics
Our systematic literature search identified 278 studies
that met the inclusion criteria. After deduplication and
exclusion of the clearly irrelevant studies, we eventually
included 11 case–control studies [19-29] involving 2,298
OSCC patients and 2,111 controls. Figure 1 shows the study
selection process. Of the 11 included studies, two recruited
OSCC patients with HPV [20,28], and three enrolled
patients with disrupted HWE [19,21,29]. Baseline charac-
teristics of the 11 studies are summarized in Table 1.
Meta-analysis
Table 2 illustrates results of the overall and subgroup
analyses. Overall, there was no association between the
TP53 codon 72 polymorphism and OSCC susceptibility
in Asians [(OR = 0.77, 95% CI = 0.48–1.22) for Arg vs. Pro;
(OR = 0.67, 95% CI = 0.31–1.43) for ArgArg vs. ProPro;
(OR = 1.14, 95% CI = 0.97–1.35) for ArgPro vs. ProPro,
Figure 2; (OR = 0.85, 95% CI = 0.53–1.34) for (ArgPro +Table 2 Overall and subgroups meta-analysis of TP53 codon
N Arg vs. Pro ArgArg vs. ProPro ArgPro vs. P
OR (95% CI) I2(%) OR (95% CI) I2 (%) OR (95% CI)
Overall 11 0.77(0.48-1.22) 96 0.67 (0.31-1.43) 94 1.14 (0.97-1.35)
HPV status
Without 9 0.81 (0.48-1.39) 97 0.75 (0.32-1.79) 95 1.20 (1.01-1.43)
With 2 0.60 (0.43-0.85) 0 0.41 (0.21-0.81) 0 0.61 (0.33-1.14)
Source of controls
PB 7 0.60 (0.26-1.38) 98 0.43 (0.11-1.64) 96 1.15 (0.92-1.44)
HB 5 1.03 (0.79-1.35) 71 1.09 (0.64-1.87) 69 1.13 (0.87-1.45)
HWE
>0.05 8 0.99 (0.82-1.20) 70 1.03 (0.70-1.50) 65 1.10 (0.91-1.32)
<0.05 3 0.44 (0.08-2.44) 99 0.27 (0.02-3.72) 97 1.36 (0.92-2.00)
OSCC, oral squamonus cell carcinoma; HPV, human papillomavirus; HB, hospital-basArgArg) vs. ProPro; and (OR = 0.34, 95% CI = 0.34–1.23)
for ArgArg vs. (ProPro + ArgPro)].
Results of the subgroup analyses stratified by source of
controls and HWE status for controls were similar to
those of the overall analyses. However, when stratified
by HPV status, a correlation between the TP53 codon
72 polymorphism and HPV infection was observed
(Table 2).
Publication bias
A funnel plot based on the ArgPro vs. ProPro genetic
model showed a relatively symmetrical distribution,
enabling us to conclude that there was no publication
bias (Figure 3).
Discussion
Arg and Pro are two distinct functional alleles that are
encoded by the TP53 codon 72, and Pro to Arg is the
most informative polymorphism in the TP53 gene and
have been found to be associated with human cancers
[10,30]. Among the published meta-analyses exploring
the association between this polymorphism and cancers,
some revealed an increased susceptibility of disease
[11-13], while others failed to find any association
[31-33]. Results from these meta-analyses indicate an
interesting phenomenon, which is that different meta-
analyses of the same cancer type could yield opposite
results. Although two meta-analyses investigating the
relationship of the TP53 codon 72 polymorphism and
oral cancer susceptibility both reached the same con-
clusions [14,15], such association among the Asian
population is unclear. Given that OSCC has a high
incidence in this population, we conducted the current
meta-analysis to further investigate if the TP53 codon 72
polymorphism plays a role in the development of OSCC.
A total of 2,298 OSCC patients and 2,111 controls
were included in our meta-analysis. Results of the overall72 polymorphism and OSCC risk in Asians
roPro (ArgPro + ArgArg) vs. ProPro ArgArg vs. (ProPro + ArgPro)
I2 (%) OR (95% CI) I2 (%) OR (95% CI) I2 (%)
0 0.85 (0.53-1.34) 87 0.64 (0.34-1.23) 95
0 0.93 (0.56-1.55) 89 0.68 (0.32-1.42) 96
0 0.54 (0.30-0.96) 0 0.54 (0.32-0.91) 0
0 0.71 (0.33-1.55) 92 0.37 (0.12-1.19) 96
17 1.06 (0.73-1.53) 52 1.22 (0.88-1.69) 59
0 1.08 (0.91-1.29) 38 0.98 (0.73-1.31) 69
0 0.61 (0.13-2.82) 95 0.23 (0.02-2.70) 98
ed; PB, population-based; HWE, Hardy Weinberg Equilibrium.
Figure 2 Forest plot. This represents the OSCC risk associated with the TP53 codon 72 polymorphism in Asians for the ArgPro vs. ProPro
genetic model.
Zeng et al. BMC Cancer 2014, 14:469 Page 5 of 7
http://www.biomedcentral.com/1471-2407/14/469population demonstrated a negative association of the
TP53 codon 72 polymorphism and OSCC, although
subgroup analysis revealed a positive correlation between
the polymorphism and HPV status in OSCC patients. Our
results are in contrast with those reported by Zhou et al.
[14], which was based on three studies reporting HPV
infection status; however, only one of these focused on an
Asian population [20]. Moreover, this earlier meta-analysis
is limited by its small sample size and mixed ethnicity. In
contrast to the two previous meta-analyses [14,15], our
meta-analysis only focused on OSCC in Asians.
The relationship between HPV and OSCC has been
previously established [34]. Our meta-analysis also found
that the TP53 codon 72 polymorphism was associated
with HPV-related OSCC susceptibility cases. However,Figure 3 Funnel plot. This represents the publication bias test based on tbecause there is no association between this polymorphism
and non-HPV OSCC cases, it is currently unclear whether
the polymorphism is merely a marker of HPV-related
OSCC. Further research is warranted to investigate this
relationship.
In 2011, Heah et al. found a significant correlation
between p53 expression and TP53 aberration in 26
OSCC cases [35]. This finding is in contrast to the results
of our present meta-analysis, although it should be noted
that TP53 contains multiple polymorphisms in addition to
the one in codon 72.
Our meta-analysis has a number of limitations. First,
like all meta-analyses, it is a secondary retrospective
study that is limited by various factors including quality
of the original studies, study population differences, andhe ArgPro vs. ProPro genetic model.
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neity is substantial, although this is extremely common in
meta-analyses of genetic association studies. We therefore
performed subgroup analyses to consider the factors that
may have contributed to the high degree of heterogeneity.
Third, our included studies lacked comprehensive genotype
information so the results of our meta-analysis were ana-
lyzed using unadjusted data; hence, we could not generate a
more accurate analysis based on other adjusted factors.
Finally, the sample size of our meta-analysis is relatively
small and studies published in languages other than
Chinese and English were not considered for inclusion.
Conclusions
Our meta-analysis showed a lack of association between
the TP53 codon 72 polymorphism and OSCC susceptibility
in Asians, although subgroup analysis demonstrated an
association between the polymorphism and HPV-related
OSCC patients. Because of the numerous limitations
of this meta-analysis including small sample size and
substantial statistical heterogeneity, our results should
be interpreted with caution and further data from
high-quality, well-conducted clinical studies of adequate
statistical power are needed.
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